Drug intelligence / Profile preview

AK-1286

Development stage: Phase 1
Lead developer: Yingli Pharma
Modality: Small Molecules
Administration: Oral

Overview

AK-1286 is an investigational small molecule drug that acts as a PARP inhibitor. It is being developed for the treatment of advanced solid tumors. The drug is currently in Phase 1 clinical trials, where its safety, tolerability, pharmacokinetics, and preliminary efficacy are being evaluated in patients with advanced solid tumors. The primary objective of these studies is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) following single and multiple oral administrations[2][3]. AK-1286 was initially developed by Shanghai Yingli Pharmaceutical.

Targets

PARP (PARP family)

Beyond the preview

Go deeper on AK-1286.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK-1286.

Explore the full profile